Elan shares jump after FDA decision

Shares in Elan have rocketed 9% today after the company received a huge boost in the US for its plans for a new treatment for multiple sclerosis.

Elan shares jump after FDA decision

Shares in Elan have rocketed 9% today after the company received a huge boost in the US for its plans for a new treatment for multiple sclerosis.

Elan today saw its Antegren drug designated for priority review and accelerated approval by the US Food and Drug Administration (FDA), sparking a surge in the company's share price.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited